Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. (Nasdaq: LFMD) is a virtual primary care and pharmacy company whose news flow centers on telehealth expansion, clinical program development, strategic collaborations, and capital markets activity. As a provider of virtual healthcare services across more than 200 conditions, LifeMD regularly issues updates on its weight management, women’s health, men’s health, behavioral health, and primary care offerings, as well as on its pharmacy and compounding pharmacy capabilities.
News about LifeMD often highlights clinical and commercial partnerships, particularly in obesity and metabolic health. The company has announced an expanded collaboration with Novo Nordisk, under which LifeMD is recognized as a telehealth partner offering FDA-approved GLP‑1 therapies such as Wegovy and Ozempic. Press releases describe new product availability, including the Wegovy oral pill, and cash-pay pricing initiatives designed to broaden access to branded GLP‑1 medications through LifeMD’s virtual weight management programs.
Investors and observers can also expect financial and corporate updates in LifeMD’s news stream. These include quarterly earnings releases, segment performance commentary, and disclosures about strategic transactions such as the divestiture of its majority interest in WorkSimpli Software LLC. The company’s transition into a pure-play virtual care and pharmacy platform, along with its efforts to strengthen its balance sheet, are recurring themes in management commentary.
Additional news items cover capital structure and governance developments, such as the authorization of dividends on the company’s 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) and the establishment of a senior secured revolving credit facility with Citizens Bank, N.A. Regulatory and reporting updates, including Forms 8‑K and notifications of late filings related to financial statement adjustments, also appear in the company’s announcements.
For those following LFMD, this news page provides a centralized view of LifeMD’s earnings reports, clinical program launches, partnership expansions, financing arrangements, and regulatory disclosures, offering context on how the company is evolving its virtual care and pharmacy platform over time.
Summary not available.
Summary not available.
LifeMD, Inc. (NASDAQ: LFMD) has launched new membership plans aimed at enhancing access to virtual primary care services. The innovative features in the proprietary mobile app now allow consumers to download it for free, gain access to a symptom checker, a discounted prescription card, and a live appointment queue for immediate virtual consultations. The company is introducing three membership tiers: FlexCare, which requires no membership fee; TotalCare, a quarterly plan that includes monthly visits; and ConciergeCare, which offers unlimited visits with a dedicated doctor. The expansion of these services is anticipated to support ongoing membership growth and positions LifeMD favorably in the evolving telehealth market, expected to see significant disruption by 2030 according to Bain and Co.
LifeMD, Inc. (NASDAQ: LFMD/LFMDP) announced a cash dividend of $0.5546875 per share on its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP). The dividend will be paid on April 17, 2023, to shareholders on record as of April 7, 2023. This move reflects the company's commitment to providing returns to its preferred shareholders. LifeMD is a telehealth provider that offers a range of virtual healthcare services across the United States, leveraging a proprietary technology platform and nationwide pharmacy network to enhance healthcare accessibility.
LifeMD reported a significant milestone in Q4 2022, achieving consolidated Adjusted EBITDA profitability for the first time, totaling $631,000. Full Year 2022 consolidated revenue reached $119.0 million, a 28% increase year-over-year, despite a $2.9 million impact from deferred telehealth shipments in Q4. The company executed a $40 million debt financing agreement with Avenue Capital, bolstering its capital position for future growth. Guidance for 2023 indicates projected revenue of $140-$150 million and Adjusted EBITDA of $12-$18 million. Notably, active telehealth subscribers grew by 22% to approximately 169,000.
LifeMD (NASDAQ: LFMD) announced securing a senior secured credit facility with Avenue Capital, providing up to $40 million, including an initial $15 million. This financing aims to support the company’s strategic growth and profitability plans, with expectations of eliminating cash burn soon. The credit agreement includes an 18-month interest-only period and a growth option up to $20 million. Additionally, LifeMD issued warrants to Avenue Capital for purchasing shares at $1.24. This investment is expected to bolster LifeMD's financial flexibility and maintain its majority interest in WorkSimpli, projected to generate over 20% EBITDA margins in 2023.
LifeMD, Inc. (NASDAQ: LFMD) has announced its financial results for the fourth quarter and full year ending December 31, 2022, will be reported after market close on March 22, 2023. This will be followed by a conference call at 4:30 PM ET to discuss the results and provide corporate updates.
LifeMD specializes in direct-to-patient telehealth services, focusing on virtual primary care and specialized treatment for various health conditions. The company aims to enhance access to affordable healthcare through its technology platform and nationwide pharmacy network.
LifeMD, Inc. (NASDAQ: LFMD) announced the appointment of Dr. Joan LaRovere to its Board of Directors, expanding the board to nine members, with seven independent directors. Dr. LaRovere brings extensive experience from top hospitals and expertise in healthcare data and technology. Her roles include Director of Innovation at Boston Children’s Hospital and Assistant Professor at Harvard Medical School. She aims to leverage her background to enhance LifeMD's mission of improving access to affordable virtual care. The press release underscores LifeMD’s commitment to using technology for advancing healthcare delivery.
LifeMD, Inc. (NASDAQ: LFMD) has announced the appointment of Jessica Friedeman as Chief Marketing Officer, succeeding Stefan Galluppi, who remains as Chief Innovation Officer. Friedeman brings nearly 20 years of experience in patient engagement and revenue growth, having previously served as CMO at Healthgrades and Mercury Healthcare. CEO Justin Schreiber expressed optimism about her role in enhancing the company's telehealth services, which have served over 177,000 patients in the past year, highlighting LifeMD's commitment to delivering personalized healthcare.
LifeMD, Inc. (NASDAQ: LFMD/LFMDP) announced a cash dividend of $0.5546875 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock. This dividend will be paid on January 17, 2023, to shareholders recorded by January 6, 2023. LifeMD is a telehealth company offering comprehensive healthcare services across all 50 states, utilizing technology to enhance accessibility and affordability of primary care, diagnostics, and treatments. This favorable announcement underscores the company's commitment to rewarding its investors.